The Food and Drug Administration (FDA) has approved Kynmobi™ (apomorphine hydrochloride; Sunovion) for the acute, intermittent treatment of off episodes in patients with Parkinson disease (PD).
The Food and Drug Administration (FDA) has approved Ongentys® (opicapone; Neurocrine Biosciences) as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson disease (PD) experiencing “off” episodes.
Long-term adjunctive treatment with amantadine may enable the levodopa regimen to be optimized in patients with Parkinson experiencing motor complications.
Droxidopa is associated with better treatment adherence than midodrine when medication cost is noninfluential.
Carbidopa/levodopa enteral suspension leads to improvement in quality of like and activities of daily living measures in patients with advanced Parkinson disease.
There were no significant differences between pimavanserin and quetiapine in time to discontinuation, mortality, or improvement in psychosis in patients with Parkinson disease and Lewy body dementia.
In the Complete Response Letter (CRL), the FDA noted that it was unable to approve the application in its present form, however the Agency did not request additional clinical studies.
Inbrija (levodopa inhalation powder; Acorda Therapeutics) is the first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson’s disease taking carbidopa/levodopa.
Based on the data, the FDA has concluded that the drug’s benefit continues to outweigh its risks for patients with hallucinations and delusions associated with Parkinson’s disease psychosis.
Nuplazid, a non-dopaminergic, selective serotonin inverse agonist, targets 5-HT2A receptors that are thought to be involved in Parkinson’s disease psychosis.
